Shamburg News · 8-K filed Nov 16, 2026, 8:08 AM EST

Corbus Pharmaceuticals Presents Additional CANYON-1 Phase 1b Data for CRB-913 Obesity Drug

CRBP · Corbus Pharmaceuticals Holdings, Inc.

  • Other event
  • Reg FD disclosure
  • Other
  • Materiality: medium

On November 16, 2026, Corbus Pharmaceuticals Holdings, Inc. announced that additional CANYON-1 Phase 1b data for CRB-913 in obesity were presented in a poster at ObesityWeek 2026 in Washington, D.C. The filing reports a mean weight loss of 5.0% at 12 weeks in the 60 mg cohort, a treatment discontinuation rate due to adverse events of 8.3%, and no serious or severe psychiatric adverse events. The Company also furnished an updated investor presentation and plans to engage with the FDA on development plans.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 8.01, 9.01, accession 0001193125-26-462186.

Written from the filing by Shamburg Markets. Figures are as reported by the company.